Updated TB Treatment Guidelines in India
The National TB Elimination Program (NTEP) in India now recommends daily dosing of first-line drugs for drug-susceptible TB and has adopted shorter all-oral bedaquiline-based regimens (BPaLM and BPaL) for drug-resistant TB, phasing out injectable agents entirely. 1
Drug-Susceptible Pulmonary Tuberculosis
Standard Adult Regimen
- Administer a 6-month course: 2 months of isoniazid, rifampin, pyrazinamide, and ethambutol (2HRZE) followed by 4 months of isoniazid and rifampin (4HR). 1
- Daily administration is strongly preferred over intermittent schedules, with directly observed therapy (DOT) provided 5–7 days per week. 1
Weight-Based Dosing (for ~70 kg adult)
| Drug | Daily Dose |
|---|---|
| Isoniazid | 300 mg (~5 mg/kg, max 300 mg) |
| Rifampin | 600 mg (~10 mg/kg, max 600 mg) |
| Pyrazinamide | 2 g (15–30 mg/kg, capped at 2 g) |
| Ethambutol | 1.2 g (15–25 mg/kg for 56–75 kg weight band) |
| Pyridoxine (vitamin B6) | 25–50 mg daily to prevent peripheral neuropathy |
These doses follow NTEP weight-band recommendations. 1
Pediatric Regimen (3 months – 16 years)
- For children with non-severe TB (no cavitation, no suspicion of MDR/RR-TB), use a 4-month regimen (2HRZ(E)/2HR) instead of the traditional 6-month course. 1
- This recommendation is supported by the 2025 ATS/CDC/ERS/IDSA guidelines with moderate certainty of evidence. 2
Baseline Monitoring Before Treatment
- Perform visual acuity (Snellen chart), color discrimination (Ishihara test), liver function tests (AST, ALT, bilirubin, alkaline phosphatase), serum creatinine, and platelet count. 1
- Ask patients monthly about visual disturbances while receiving ethambutol. 1
Drug-Resistant Tuberculosis
Diagnostic Prerequisite
- Molecular testing for fluoroquinolone resistance (e.g., Xpert MTB/XDR, TrueNat, or next-generation sequencing) must be performed before initiating any shorter regimen. 1, 3
Rifampin-Resistant, Fluoroquinolone-Susceptible TB (MDR/RR-TB)
For adolescents ≥14 years and adults, use the 6-month all-oral BPaLM regimen (bedaquiline + pretomanid + linezolid + moxifloxacin) instead of prolonged 15-month or longer regimens. 1
BPaLM Dosing Schedule (26 weeks)
| Drug | Dose & Schedule |
|---|---|
| Bedaquiline | 400 mg daily × 2 weeks, then 200 mg three times weekly (≥48 h between doses) for remaining 24 weeks |
| Pretomanid | 200 mg daily |
| Linezolid | 600 mg daily |
| Moxifloxacin | 400 mg daily |
- All drugs must be taken with food and administered seven days per week. 1
- Avoid co-administration with milk, antacids, or other cation-containing products because they impair absorption. 1
- Directly observed therapy (DOT) is mandatory for five of seven days per week. 1
Evidence for BPaLM
- The TB-PRACTECAL trial showed unfavorable outcomes in only 11% of BPaLM patients versus 48% with standard care (risk difference −37 percentage points). 2
- Real-world implementation studies in India and globally report treatment success rates of 95.3%. 2
- Grade ≥3 adverse events occurred in 19% of BPaLM patients versus 59% with standard care. 2
Rifampin-Resistant TB with Fluoroquinolone Resistance or Intolerance
Use the 6-month BPaL regimen (bedaquiline + pretomanid + linezolid, without moxifloxacin) for patients with ≤1 month prior exposure to bedaquiline or linezolid, achieving 90–100% treatment success. 1
Longer MDR-TB Regimens (when BPaL/BPaLM unsuitable)
- Include all three Group A agents—levofloxacin/moxifloxacin, bedaquiline, and linezolid—together with at least one Group B agent to ensure ≥4 effective drugs at treatment start. 1
- Bedaquiline and linezolid are now strongly recommended (upgraded from conditional) for longer MDR-TB regimens in adults ≥18 years. 1
- Kanamycin and capreomycin must not be used in MDR/RR-TB treatment; injectable agents have been phased out. 1, 3
Isoniazid-Resistant, Rifampin-Susceptible TB
- Use a 6-month regimen: rifampin, ethambutol, pyrazinamide, and levofloxacin. 1
- Injectable agents such as streptomycin should not be added. 1
Monitoring During BPaLM/BPaL Treatment
Baseline Assessment
- Perform an electrocardiogram (ECG) to assess QTc interval prior to starting therapy. 2
Ongoing Monitoring
- Monthly complete blood counts to detect linezolid-related myelosuppression. 2
- Monthly visual acuity and color discrimination testing while on linezolid to monitor for optic neuropathy. 2
- Periodic ECG monitoring for QT prolongation (both bedaquiline and moxifloxacin can prolong QTc). 2
- Liver function tests if symptoms of hepatotoxicity develop (fever, malaise, vomiting, jaundice). 2
Management of Linezolid-Related Myelosuppression
- If significant anemia, thrombocytopenia, or neutropenia occurs, reduce the linezolid dose or interrupt therapy until hematologic parameters improve. 2
Special Situations
Tuberculous Pericarditis
- Treat with the standard 6-month four-drug regimen (HRZE) because pericardial TB is a severe manifestation. 1
- Adjunctive corticosteroids: Prednisone 1–2 mg/kg/day for 5–7 days, then taper over 6–8 weeks. 1
- Pericardiocentesis for cardiac tamponade or symptomatic large effusions not responding to medical therapy. 1
- Pericardiectomy if clinical status fails to improve after 4–8 weeks of therapy or if chronic constrictive pericarditis develops. 1
- In TB-endemic regions like India, empiric anti-TB chemotherapy is recommended for exudative pericardial effusions after other causes have been excluded. 1
Tuberculous Meningitis
- Administer rifampin and isoniazid for a total of 12 months in all patients with tuberculous meningitis. 4
- Add pyrazinamide for at least the first 2 months because it penetrates cerebrospinal fluid (CSF) well. 4
- Include a fourth drug during the initial 2 months—choose streptomycin, ethambutol (~15 mg/kg), or ethionamide—to broaden coverage and address possible resistance. 4
- Give corticosteroids to patients with stage II or III disease (confused, neurologic signs, or comatose) to reduce inflammatory injury. 4
- Preferred regimen: dexamethasone 6–12 mg/day or prednisone 60–80 mg/day, tapered over 4–8 weeks. 4
Common Pitfalls to Avoid
- Do not apply the standard 6-month pulmonary TB regimen to meningitis, as it is insufficient for CNS disease; use 12 months instead. 4
- Do not use once-weekly isoniazid 900 mg with rifapentine 600 mg in the continuation phase because it yields inferior treatment outcomes. 1
- Do not add injectable agents to isoniazid-resistant, rifampin-susceptible TB regimens. 1
- Do not use kanamycin or capreomycin in MDR/RR-TB treatment; they have been excluded from current guidelines. 1
- Always perform lumbar puncture in patients with miliary TB to detect CNS involvement, given the high rate of hematogenous spread to the meninges. 4
Implementation Context in India
- India transitioned to daily treatment for drug-sensitive TB starting in 2015, implementing this policy in five states initially. 5
- The March 2021 PMDT guidelines represent a paradigm shift, making DR-TB treatment easier and more efficient, especially during the COVID-19 pandemic. 3
- India accounts for 25% of the global burden of MDR-TB, with historical treatment success rates of only 46% under older regimens, underscoring the urgent need for shorter, safer, and more effective regimens like BPaLM. 6
- By 2026, BPaL/M is projected to be used in 78% of DR-TB patients globally, with India being a key adopter. 7